NeurologyLive® Friday 5 — May 31, 2024

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 31, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Understanding Silent Progression in Multiple Sclerosis: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center discussed the early-onset progression of multiple sclerosis and emphasized the need for targeted therapies in this patient population. [WATCH TIME: 6 minutes]

Understanding Silent Progression in Multiple Sclerosis: Bruce Cree, MD, PhD, MAS, FAAN

2: Researching Dravet Syndrome Biomarkers to Advance Treatment: Christos Papadelis, PhD

The director of research in the Jane and John Justin Neurosciences Center at Cook Children's Health Care System talked about ongoing research on biomarkers to enhance treatment and improve cognitive outcomes. [WATCH TIME: 6 minutes]

Researching Dravet Syndrome Biomarkers to Advance Treatment: Christos Papadelis, PhD

3: NeurologyLive® Clinician of the Month Spotlight: Merit Cudkowicz, MD, MSc

As part of our monthly clinician spotlight, NeurologyLive® highlighted neuromuscular disorder expert Merit Cudkowicz, MD, MSc, chair of neurology at Massachusetts General Hospital.

NeurologyLive® Clinician of the Month Spotlight: Merit Cudkowicz, MD, MSc

4: NeuroVoices: Michael Levy, MD, PhD, on Comparing Patient Outcomes of Inebilizumab and Rituximab in NMOSD

In this week's NeuroVocies Q&A, the associate professor of neurology at Harvard Medical School talked about results from a recent study that evaluated the efficacy of inebilizumab versus rituximab in treating NMOSD.

NeuroVoices: Michael Levy, MD, PhD, on Comparing Patient Outcomes of Inebilizumab and Rituximab in NMOSD

5: Utilization of APOE4 Genotype in Management of Alzheimer’s Disease

In episode 8 of a Peer Exchange video series, medical experts discussed the application of ApoE gene polymorphism and copy number data in managing Alzheimer disease (AD), highlighting its relevance for individuals with a family history of AD, and symptomatic patients.

Utilization of APOE4 Genotype in Management of Alzheimer’s Disease
Related Videos
Patricia K. Coyle, MD
Video 2 - 5 KOLs are featured in "Natural History of Spinal Muscular Atrophy"
Video 1 - 5 KOLs are featured in "Clinical Features and Phenotypes of Spinal Muscular Atrophy"
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
 Brian G. Weinshenker, MD, FRCP
© 2024 MJH Life Sciences

All rights reserved.